Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 19/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3562034 | 0.95 | CETP (0.61) | CETPNR1I2PTGDR2 | |
| SCHEMBL3554119 | 0.91 | CETP (0.64) | CETPNR1I2PTGDR2 | |
| SCHEMBL3553073 | 0.90 | CETP (0.61) | CETPNR1I2PTGDR2 | |
| SCHEMBL531985 | 0.86 | CETP (0.60) | CETPNR1I2 | |
| SCHEMBL531459 | 0.86 | CETP (0.58) | CETPNR1I2 | |
| SCHEMBL4011739 | 0.86 | CETP (0.67) | CETPNR1I2 | |
| SCHEMBL3552859 | 0.84 | CETP (0.68) | CETPNR1I2PTGDR2 | |
| SCHEMBL4009039 | 0.84 | CETP (0.68) | CETPNR1I2 | |
| SCHEMBL17994030 | 0.83 | CETP (0.72) | CETPNR1I2 | |
| SCHEMBL20768070 | 0.83 | CETP (0.66) | CETPNR1I2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737811-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-1737811-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-10 | — | — | EP | disclosed |
| US-8193365-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193365-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193365-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-1979331-B1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8076364-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | NAKAMURA YOSHINORI | 2011-04-21 | — | — | US | disclosed |
| US-7906517-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20100249024-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1979331-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| EP-1817297-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | Pfizer Products Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| EP-1737811-A1 | CETP INHIBITORS | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006056854-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2005100298-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | CETP, MTTP, APOB | CETP 1/4885NR1I2 206/4885PTGDR2 4540/4885 |
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | CETP 1/4885NR1I2 86/4885PTGDR2 4585/4885 |
| US-20100249024-A1 | CETP INHIBITORS | CETP, APOB, NPC1 | CETP 1/4885NR1I2 86/4885PTGDR2 4585/4885 |
| US-20090029994-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | CETP 1/4885NR1I2 206/4885PTGDR2 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.